Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model

Satoru Morimoto, Koichi Saeki, Masaru Takeshita, Kunio Hirano, Mariko Shirakawa, Yumiko Yamada, Shiho Nakamura, Fumiko Ozawa, Hideyuki Okano

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The coronavirus disease 2019 (COVID-19) epidemic remains worldwide. The usefulness of the intranasal vaccine and boost immunization against severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) has recently received much attention. We developed an intranasal SARS-CoV-2 vaccine by loading the receptor binding domain of the S protein (S-RBD) of SARS-CoV-2 as an antigen into an F-deficient Sendai virus vector. After the S-RBD-Fd antigen with trimer formation ability was intranasally administered to mice, S-RBD-specific IgM, IgG, IgA, and neutralizing antibody titers were increased in serum or bronchoalveolar lavage fluid for 12 weeks. Furthermore, in mice that received a booster dose at week 8, a marked increase in neutralizing antibodies in the serum and bronchoalveolar lavage fluid was observed at the final evaluation at week 12, which neutralized the pseudotyped lentivirus expressing the SARS-CoV-2 spike protein, indicating the usefulness of the Sendai virus-based SARS-CoV-2 intranasal vaccine.

Original languageEnglish
Pages (from-to)29-41
Number of pages13
JournalGenes to Cells
Issue number1
Publication statusPublished - 2023 Jan


  • SARS-CoV-2
  • Sendai virus
  • intranasal vaccine
  • neutralizing antibodies

ASJC Scopus subject areas

  • Genetics
  • Cell Biology


Dive into the research topics of 'Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model'. Together they form a unique fingerprint.

Cite this